LLY

1,038.01

+2.17%↑

JNJ

248.46

+2.47%↑

ABBV

230.69

+2.61%↑

NVS

169.41

+2.25%↑

MRK

123.81

+3.55%↑

LLY

1,038.01

+2.17%↑

JNJ

248.46

+2.47%↑

ABBV

230.69

+2.61%↑

NVS

169.41

+2.25%↑

MRK

123.81

+3.55%↑

LLY

1,038.01

+2.17%↑

JNJ

248.46

+2.47%↑

ABBV

230.69

+2.61%↑

NVS

169.41

+2.25%↑

MRK

123.81

+3.55%↑

LLY

1,038.01

+2.17%↑

JNJ

248.46

+2.47%↑

ABBV

230.69

+2.61%↑

NVS

169.41

+2.25%↑

MRK

123.81

+3.55%↑

LLY

1,038.01

+2.17%↑

JNJ

248.46

+2.47%↑

ABBV

230.69

+2.61%↑

NVS

169.41

+2.25%↑

MRK

123.81

+3.55%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Open

SectorHealthcare

433.89 -1.69

Buy Sell

Overview

Share price change

24h

Current

Min

428.28

Max

447.35

Key metrics
By Trading Economics
Income	56M -59M
Sales	34M 321M
Profit margin	-18.243
Employees	915
EBITDA	21M -86M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+55.86% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	-611M 9.9B
Previous open	435.58
Previous close	433.89

News Sentiment

By Acuity

29%

71%

73 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 lut 2026, 22:04 UTC

Earnings

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 lut 2026, 23:40 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 lut 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 lut 2026, 23:32 UTC

Earnings

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 lut 2026, 23:19 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

26 lut 2026, 23:12 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 lut 2026, 23:01 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 23:00 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 lut 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 lut 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26 lut 2026, 22:33 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 lut 2026, 22:13 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 lut 2026, 21:59 UTC

Earnings

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 lut 2026, 21:58 UTC

Acquisitions, Mergers, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26 lut 2026, 21:49 UTC

Earnings

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 lut 2026, 21:45 UTC

Earnings

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 lut 2026, 21:44 UTC

Earnings

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 lut 2026, 21:44 UTC

Earnings

Coles Expects Market to Remain Highly Competitive

26 lut 2026, 21:44 UTC

Earnings

Coles Says Supermarket Customers Remain Value Oriented

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 lut 2026, 21:43 UTC

Earnings

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 lut 2026, 21:42 UTC

Acquisitions, Mergers, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 lut 2026, 21:41 UTC

Earnings

Acquisitions, Mergers, Takeovers

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

55.86% upside

12 Months Forecast

Average 694.9 USD 55.86%

High 964 USD

Low 529 USD

Based on 11 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

Buy

Hold

Sell

Based on 11 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

73 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.